Drastop Injection 100mg / 2ml amp ml 10 units

Description

Composition
Active substance:
Sodium chondroitin sulfate – 100 mg ;.
Excipients:
Benzyl alcohol – 12 mg, 1% sodium hydroxide or 0.1 M hydrochloric acid solution – to pH 6.5 – 6.8 Water for injection – up to 1 ml.
Description:
Clear, slightly yellowish solution.
Product form:
Solution for intramuscular administration of 100 mg / ml.
2 ml of the drug in the vial of colorless glass fracture ring c white 5 ampoules in blisters. 1 or 2 blisters together with instructions for use in a cardboard package.
Contraindications
– increased sensitivity to the drug; – bleeding, a tendency to bleeding; – thrombophlebitis; -children’s age (efficacy and safety have not been established).
Dosage
100 mg / ml
Indications
Degenerative-dystrophic diseases of joints and spine: – osteoarthritis of peripheral joints; – intervertebral osteoarthritis and osteochondrosis.
Pediatric use
Data on the efficacy and safety of the drug in children DRASTOP not covered at present.
Interaction with other drugs
May increase the action of indirect anticoagulants, antiplatelet agents, fibrinolytic agents, which requires more frequent monitoring of blood coagulation parameters when used together.
Overdose
Overdosing is not described and is unlikely.
pharmachologic effect
Pharmacological group:
Tissue repair promoter.
Pharmacodynamics:
Has hondrostimuliruyuschee, regenerating, anti-inflammatory and analgesic effect. Chondroitin sulfate is involved in the construction of the basic substance of cartilage and bone. Has chondroprotective properties, increases metabolism in hyaline cartilage and fibrous, subhondrialnoy bone; inhibits enzymes that cause degradation (destruction) of the articular cartilage; It stimulates the production of proteoglycans by chondrocytes. Helps to reduce emissions in the synovial fluid of mediators of inflammation and pain factors, suppresses secretion of leukotrienes and prostaglandins. Slows bone resorption and reducing calcium loss, accelerates bone regeneration. Chondroitin sulfate slows the progression of osteoarthritis and osteoarthritis. Promotes restoration of the joint capsule and cartilage surfaces of the joints, prevents the collapse of the connective tissue, normalizes the production of joint fluid.
In applying the drug reduced pain and improved mobility of the affected joints, the therapeutic effect lasts for a long time after the end of therapy. In the treatment of degenerative changes of the joints accompanied by secondary synovitis, the effect has been observed in 2-3 weeks from the date of commencement of the course. With structural similarity to heparin may potentially inhibit the formation of fibrin clots and in the synovial microvasculature subhondrialnom.
Pharmacokinetics:
After the / m of sodium chondroitin sulfate is readily absorbed. Already 30 minutes after injection, it is detected in significant concentrations in blood. The maximum concentration of sodium chondroitin sulphate is achieved in plasma 1 hour, then gradually decreases during 2 days.
Sodium chondroitin sulfate is accumulated mainly in cartilage forming joints. The synovium is not an obstacle for the penetration of the drug into the joint cavity. After 15 minutes after the / im injection of sodium chondroitin sulfate found in the synovial fluid then penetrates into the articular cartilage where its maximum concentration is achieved after 48 hours.
Pregnancy and breast-feeding
Do not use the drug during pregnancy. During treatment, breast-feeding should be discontinued due to lack of data.
Conditions of supply of pharmacies
On prescription.
side effects
Allergic reactions (pruritus, erythema, urticaria, dermatitis), pain and hemorrhage in the injection site, dyspepsia, angioedema.
special instructions
To achieve the necessary stable clinical effect for at least 25 injections of the drug. The effect persists for several months after treatment. For the prevention of exacerbations used repeated courses of treatment. When allergic reactions or hemorrhages treatment should cease.
The effect on the ability to operate vehicles, machinery
DRASTOP no effect on the ability to manage road and engage in potentially hazardous activities that require attention.
Storage conditions
Store at a temperature not higher than 25 ° C.
Keep out of the reach of children!.
Dosing and Administration
The drug is administered / m and 1 ml (100 mg of chondroitin sodium sulfate) every other day. With good tolerance dose was increased to 2 ml (200 mg of chondroitin sodium sulfate), starting from the fourth injection. The course of treatment – 25-30 injections. If necessary, may repeat courses of treatment after 6 months.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist